Oncology/Cancer Drugs Market by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy) and Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Others): Global Opportunity Analysis and Industry Forecast, 2018 - 2025
- Published Date: 2020-10-18
- Report ID: 3380
- Pages: 252
-
Format:
Oncology Drugs Market Overview:
The global oncology/cancer drugs market was valued at $97,401 million in 2017, and is estimated to reach at $176,509 million by 2025, registering a CAGR of 7.6% from 2018 to 2025.
Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option to treat various cancer types, especially blood cancer (leukemia). Rise in incidence of various cancer conditions, increase in popularity of advance therapies (biological and targeted drug therapies), and surge in geriatric population worldwide are the key factors driving the growth of the global oncology/cancer drugs market. Furthermore, rise in cancer awareness and availability of cancer drugs are expected to boost the market growth.
However, high cost involved in new drug development coupled with threat of failure & adverse effects associated with cancer drugs therapies is expected to restrain the growth of the market. Conversely, high potential of emerging economies and increase in number of pipeline products are expected to provide new opportunities for market players in future.
The global oncology/cancer drugs market is segmented based on drug class type, indication, and region. Depending on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. By indication, it is categorized into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers.
Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Key Benefits for Oncology Drugs Market:
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
Oncology Drugs Key Market Segments:
By Drug Class Type
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
By Indication
Lung Cancer
Stomach Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Esophagus Cancer
Cervical Cancer
Kidney Cancer
Bladder Cancer
Other Cancers
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
India
China
Japan
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
Rest of LAMEA
List of Key Players Profiled in the Report
AbbVie Inc.
Astellas Pharma Inc.
AstraZeneca PLC
Bristol-Myers Squibb Company
Celgene Corporation
F. Hoffmann-La Roche Ltd.
Johnson & Johnson (Janssen Global Services, LLC,)
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
Sanofi
Amgen Inc.
Bayer AG
Exelixis, Inc.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies, 2017
3.3. Top player positioning, 2017
3.4. Porters five forces analysis
3.5. Clinical trials
3.6. Patent analysis (2015-2018)
3.6.1. Patent analysis, world
3.6.2. Patent analysis, by year
3.7. Market dynamics
3.7.1. Drivers
3.7.1.1. Rise in incidence of cancer across the globe
3.7.1.2. Surge in global geriatric population
3.7.1.3. Increase in government expenditures on healthcare
3.7.2. Restraints
3.7.2.1. Adverse effects associated with the use of cancer drugs
3.7.3. Opportunities
3.7.3.1. Untapped emerging economies
3.7.3.2. Increase in number of pipeline drugs
3.7.4. Impact Analyses
CHAPTER 4: ONCOLOGY/ CANCER DRUGS MARKET, BY DRUG CLASS TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Chemotherapy
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Targeted Therapy
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Immunotherapy (Biologic Therapy)
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Hormonal Therapy
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
CHAPTER 5: ONCOLOGY/ CANCER DRUGS MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Lung Cancer
5.2.1. Market size and forecast, by region
5.2.2. Market share analysis, by country
5.3. Stomach Cancer
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Colorectal Cancer
5.4.1. Market size and forecast, by region
5.4.2. Market share analysis, by country
5.5. Breast Cancer
5.5.1. Market size and forecast, by region
5.5.2. Market share analysis, by country
5.6. Prostate Cancer
5.6.1. Market size and forecast, by region
5.6.2. Market share analysis, by country
5.7. Liver Cancer
5.7.1. Market size and forecast, by region
5.7.2. Market share analysis, by country
5.8. Esophagus Cancer
5.8.1. Market size and forecast, by region
5.8.2. Market share analysis, by country
5.9. Cervical Cancer
5.9.1. Market size and forecast, by region
5.9.2. Market share analysis, by country
5.10. Kidney Cancer
5.10.1. Market size and forecast, by region
5.10.2. Market share analysis, by country
5.11. Bladder Cancer
5.11.1. Market size and forecast, by region
5.11.2. Market share analysis, by country
5.12. Other Cancers
5.12.1. Market size and forecast, by region
5.12.2. Market share analysis, by country
CHAPTER 6: ONCOLOGY/ CANCER DRUGS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. oncology/cancer drugs market, by drug class type
6.2.2.1.2. U.S. oncology/cancer drugs market, by indication
6.2.2.2. Canada
6.2.2.2.1. Canada oncology/cancer drugs market, by drug class type
6.2.2.2.2. Canada oncology/cancer drugs market, by indication
6.2.2.3. Mexico
6.2.2.3.1. Mexico oncology/cancer drugs market, by drug class type
6.2.2.3.2. Mexico oncology/cancer drugs market, by indication
6.2.3. Market size and forecast, by drug class type
6.2.4. Market size and forecast, by indication
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by country
6.3.2.1. Germany
6.3.2.1.1. Germany oncology/cancer drugs market, by drug class type
6.3.2.1.2. Germany oncology/cancer drugs market, by indication
6.3.2.2. France
6.3.2.2.1. France oncology/cancer drugs market, by drug class type
6.3.2.2.2. France oncology/cancer drugs market, by indication
6.3.2.3. UK
6.3.2.3.1. UK oncology/cancer drugs market, by drug class type
6.3.2.3.2. UK oncology/cancer drugs market, by indication
6.3.2.4. Italy
6.3.2.4.1. Italy oncology/cancer drugs market, by drug class type
6.3.2.4.2. Italy oncology/cancer drugs market, by indication
6.3.2.5. Spain
6.3.2.5.1. Spain oncology/cancer drugs market, by drug class type
6.3.2.5.2. Spain oncology/cancer drugs market, by indication
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe oncology/cancer drugs market, by drug class type
6.3.2.6.2. Rest of Europe oncology/cancer drugs market, by indication
6.3.3. Market size and forecast, by drug class type
6.3.4. Market size and forecast, by indication
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Japan oncology/cancer drugs market, by drug class type
6.4.2.1.2. Japan oncology/cancer drugs market, by indication
6.4.2.2. China
6.4.2.2.1. China oncology/cancer drugs market, by drug class type
6.4.2.2.2. China oncology/cancer drugs market, by indication
6.4.2.3. Australia
6.4.2.3.1. Australia oncology/cancer drugs market, by drug class type
6.4.2.3.2. Australia oncology/cancer drugs market, by indication
6.4.2.4. India
6.4.2.4.1. India oncology/cancer drugs market, by drug class type
6.4.2.4.2. India oncology/cancer drugs market, by indication
6.4.2.5. South Korea
6.4.2.5.1. South Korea oncology/cancer drugs market, by drug class type
6.4.2.5.2. South Korea oncology/cancer drugs market, by indication
6.4.2.6. Rest of Asia-Pacific
6.4.2.6.1. Rest of Asia-Pacific oncology/cancer drugs market, by drug class type
6.4.2.6.2. Rest of Asia-Pacific oncology/cancer drugs market, by indication
6.4.3. Market size and forecast, by drug class type
6.4.4. Market size and forecast, by indication
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil oncology/cancer drugs market, by drug class type
6.5.2.1.2. Brazil oncology/cancer drugs market, by indication
6.5.2.2. Saudi Arabia
6.5.2.2.1. Saudi Arabia oncology/cancer drugs market, by drug class type
6.5.2.2.2. Saudi Arabia oncology/cancer drugs market, by indication
6.5.2.3. South Africa
6.5.2.3.1. South Africa oncology/cancer drugs market, by drug class type
6.5.2.3.2. South Africa oncology/cancer drugs market, by indication
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA oncology/cancer drugs market, by drug class type
6.5.2.4.2. Rest of LAMEA oncology/cancer drugs market, by indication
6.5.3. Market size and forecast, by drug class type
6.5.4. Market size and forecast, by indication
CHAPTER 7: COMPANY PROFILES
7.1. AbbVie Inc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product Portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. Astellas Pharma Inc.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product Portfolio
7.2.5. Business performance
7.3. AstraZeneca PLC
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product Portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments
7.4. Bristol-Myers Squibb Company
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product Portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. Celgene Corporation
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product type Portfolio
7.5.5. Business performance
7.6. F. HOFFMANN-LA ROCHE LTD.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. JOHNSON & JOHNSON (Janssen Global Services, LLC,)
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product Portfolio
7.7.5. Business performance
7.8. Merck & Co., Inc.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product Portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. Novartis AG
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product Portfolio
7.9.5. Business performance
7.10. Pfizer Inc.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product Portfolio
7.10.5. Business performance
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
